MilliporeSigma, Merck's life science division, received a Notice of Intention to Grant from the European Patent Office for its CRISPR technology, which allows researchers to replace mutations with a functional sequence. The approval will make this only the second patent to be awarded in Europe for gene-editing technology.
European patent to be granted to MilliporeSigma's CRISPR technology
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.